Novo Nordisk's Buyback Blitz and Pipeline Promise Drive Weekly Surge, But Overbought Signal Looms
27.06.2026 - 14:33:18 | boerse-global.de
Novo Nordisk has clawed back roughly 40% from its March nadir, with the stock rallying more than 8% in the past week alone to close at €42.19 on Friday. The recovery reflects a potent combination of capital-return firepower and advancing clinical programs, even as technical warning lights begin to flash.
The Danish pharma group has been aggressively repurchasing its own shares since February, snapping up nearly 21 million equities in a programme worth 15 billion Danish kroner that runs for a full year. The buying has been so sustained that the company now holds close to 1% of its total share capital in treasury. Such moves tighten supply and underpin the stock, a tactic that appears to be paying off as investors regain confidence.
Away from the buyback, Novo Nordisk is also investing in longer-term sustainability. Last week it unveiled a 20-year partnership with Brazilian firm re.green to reforest roughly 500 hectares in the state of Pará, with the aim of generating 87,000 carbon credits through restoration. While the project is environmentally focused, it reinforces the group’s broader narrative of responsible growth.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
On the pipeline front, the company is testing Cagrilintide, a weekly injection designed for patients who drop out of conventional GLP-1 therapies due to nausea. The move targets a broader slice of the obesity market. More pivotal, however, is the impending US regulatory verdict on the combination therapy CagriSema. The Food and Drug Administration is expected to rule in the fourth quarter, after recent trial data demonstrated strong weight loss and improved blood sugar control.
Even a mid-June cybersecurity breach, in which hackers accessed pseudonymised patient data, has failed to derail the share price. The core business continues to operate normally and a forensic investigation remains ongoing.
Technically, the rally has entered dangerous territory. The relative-strength index now stands at 71.3 — firmly in overbought territory. While the stock sits comfortably above its 50-day moving average of €37.80, it still trades roughly 27% lower on a year-to-date basis. Bulls must now hold the 200-day line near €41 as support.
The next major catalyst arrives on 5 August, when Novo Nordisk reports second-quarter earnings. The focus will be on patient adherence to the oral Wegovy pill, particularly whether users stay on higher doses long enough to convert prescriptions into reliable revenue streams. Until then, the buyback machine and the FDA countdown are likely to keep the story alive.
Ad
Novo Nordisk Stock: New Analysis - 27 June
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
